Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, which is the leading cancer killer in the world. Despite the recent advances in its diagnosis and therapy, the prognosis of NSCLC patients remains very poor, mainly due to the development of drug resistance and metastasis. Both the chemokine network and the matrix metalloproteinase (MMP) system play important roles in cancer cell metastasis. The disruption of CCL2/CCR2 chemokine signaling has been shown to suppress cancer cellviability and metastasis. CCL2-neutralizing antibodies, which have shown promising therapeutic efficacy in several cancer models, are not widely used due to technical issues. CCR2 antagonism has thus become an alternative method for cancer treatment. However, the effect of CCR2 antagonists on NSCLC progression remains poorly understood. Here, we investigated the effect of CCR2 antagonist (CAS445479-97-0) on the proliferation, migration and invasion of human lung adenocarcinoma A549 cells by using WST-1 cell viability assay, transwell migration assay, wound healing scratch assay and Matrigel invasion assay. We demonstrated that CCL2 treatment promoted A549 cell viability, motility and invasion by upregulating MMP-9 expression and that this induction was significantly suppressed by CAS 445479-97-0. Taken together, our data suggested that the CCR2 antagonist would be a potential drug for treating CCR2-positive NSCLC patients.
基金：
Guangdong province, China [A2013208]
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区医学
小类|2 区肿瘤学3 区细胞生物学
最新[2023]版：
无
第一作者：
第一作者机构：[1]Sun Yat Sen Univ, Affiliated Hosp 3, Dept Cardiothorac Surg, Guangzhou 510630, Guangdong, Peoples R China;
通讯作者：
通讯机构：[1]Sun Yat Sen Univ, Affiliated Hosp 3, Dept Cardiothorac Surg, Guangzhou 510630, Guangdong, Peoples R China;[5]Univ Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, San Antonio, TX 78229 USA
推荐引用方式(GB/T 7714)：
An Jun,Xue Ying,Long Meijun,et al.Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells[J].ONCOTARGET.2017,8(24):39230-39240.doi:10.18632/oncotarget.16837.
APA：
An, Jun,Xue, Ying,Long, Meijun,Zhang, Ge,Zhang, Junhang&Su, Hang.(2017).Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells.ONCOTARGET,8,(24)
MLA：
An, Jun,et al."Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells".ONCOTARGET 8..24(2017):39230-39240
